Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Next-Generation Oncology Devices And Solutions Market Value Growth And Long-Term Outlook
The next-generation oncology devices and solutions market has experienced significant expansion in recent years. This market is projected to increase from $16.41 billion in 2025 to $19.46 billion in 2026, registering a compound annual growth rate (CAGR) of 18.6%. Historically, this growth has been driven by several key factors, such as the rising global incidence of cancer, the enhancement of molecular diagnostic capabilities, the wider availability of advanced oncology testing tools, the development of hospital-based cancer care programs, and the increasing embrace of targeted therapies.
The next-generation oncology devices and solutions market size is anticipated to experience substantial expansion over the upcoming years. It is projected to reach $38.19 billion by 2030, growing at a compound annual growth rate (CAGR) of 18.4%. This anticipated growth is driven by factors such as the increasing demand for personalized cancer treatment, heightened investments in genomic diagnostics, the expansion of early screening programs, the growing integration of AI in oncology workflows, and advancements in biomarker-based cancer management. Prominent trends observed during this forecast period include the increasing adoption of precision oncology platforms, the rising use of NGS-based cancer diagnostics, the growing integration of digital pathology solutions, the expansion of personalized cancer treatment approaches, and an enhanced focus on early detection technologies.
Get A Free Sample Report With In-Depth Market Insights:
Next-Generation Oncology Devices And Solutions Market Growth Factors Behind Sustained Expansion
The expanding incidence of cancer is projected to boost the next-generation oncology devices and solutions market in the future. Cancer, a condition characterized by the uncontrolled proliferation of abnormal cells that can disseminate throughout the body and impair normal functions, is seeing an increase in its occurrence. This uptick in cancer prevalence is primarily attributed to aging demographics, given that the likelihood of developing cancer escalates with advancing age. Modern oncology devices and solutions play a crucial role in managing this growing prevalence through facilitating earlier detection, more accurate diagnoses, and customized treatment approaches. As an illustration, the American Cancer Society, a US-based nonprofit organization, reported in January 2024 an estimate of over 611,000 cancer fatalities in the United States, which translates to more than 1,600 deaths linked to cancer each day. Consequently, the rising prevalence of cancer will propel the expansion of the next-generation oncology devices and solutions market.
Next-Generation Oncology Devices And Solutions Market Segment Breakdown: Which Categories Lead On Revenue?
The next-generation oncology devices and solutions market covered in this report is segmented –
1) By Cancer Type: Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer
2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), DNA Microarrays, Multiplexing, Other Technologies
3) By Application: Screening And Early Detection, Prognostics And Monitoring, Therapy Selection, Recurrence Monitoring, Other Applications
4) By End Use: Hospitals And Clinics, Diagnostic Laboratories, Academic And Research Institutions, Other End Uses
Subsegments:
1) By Breast Cancer: Invasive Ductal Carcinoma, Invasive Lobular Carcinoma, Triple-Negative Breast Cancer, HER2-Positive Breast Cancer
2) By Cervical Cancer: Squamous Cell Carcinoma, Adenocarcinoma, Adenosquamous Carcinoma
3) By Colorectal Cancer: Colon Cancer, Rectal Cancer, Metastatic Colorectal Cancer
4) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Squamous Cell Lung Carcinoma
Next-Generation Oncology Devices And Solutions Market Industry Trends Fueling Future Revenue Growth
Major companies in the next-generation oncology devices and solutions market are focusing on technological advancements such as next-generation sequencing (NGS) target enrichment solutions to improve the detection of rare genetic variants, enhance sequencing accuracy, and accelerate cancer diagnosis and treatment decisions. Next-generation sequencing (NGS) target enrichment solutions are techniques that selectively capture and concentrate specific regions of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) for sequencing, enabling more accurate and efficient analysis of genetic variants associated with diseases such as cancer. For instance, in April 2025, Integrated DNA Technologies (IDT), a US-based biotechnology company, unveiled the xGen Hybridization and Wash v3 Kit, a transformative hybridization capture solution designed to accelerate cancer research by streamlining next-generation sequencing (NGS) workflows. This innovative kit significantly reduces the hybridization time to just one hour, enabling researchers to complete sample preparation and proceed to sequencing within a single workday. By eliminating the need for heated buffers and cutting hands-on time by 20%, the solution is highly automation-friendly and well-suited for high-throughput applications.
Next-Generation Oncology Devices And Solutions Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the next-generation oncology devices and solutions market are Johnson & Johnson Services Inc., Siemens AG, Merck & Co. Inc., Thermo Fisher Scientific Inc., Novartis AG, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, Elekta AB, Myriad Genetics Inc., Takara Bio USA Inc., NeoGenomics Inc., Guardant Health Inc., Accuray Incorporated, SOPHiA GENETICS SA, Paige.AI Inc., Deep Bio Inc., Lucida Medical Ltd.
View The Full Next-Generation Oncology Devices And Solutions Market Report:
Next-Generation Oncology Devices And Solutions Market Geographic Spread And Regional Opportunities
North America was the largest region in the next-generation oncology devices and solutions market in 2025. The regions covered in the next-generation oncology devices and solutions market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
